Patents by Inventor Anthony Ivetac

Anthony Ivetac has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2-AMINO IMIDAZOLE DERIVATIVES AS PRMT5 INHIBITORS
    Publication number: 20260109709
    Abstract: Disclosed herein are 2-amino imidazole derivatives. These compounds inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In addition to the compounds, disclosed herein are pharmaceutical compositions containing the compounds, and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: November 4, 2022
    Publication date: April 23, 2026
    Inventors: Svitlana KULYK, Christopher Ronald SMITH, Anthony IVETAC, John David LAWSON
  • TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS
    Publication number: 20260035389
    Abstract: The present invention relates to compounds that inhibit at least one of KRas wild type, KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: August 13, 2025
    Publication date: February 5, 2026
    Inventors: Xiaolun WANG, Anthony IVETAC, Svitlana KULYK, John David LAWSON, Matthew Arnold MARX, Christopher Ronald SMITH
  • SALTS OF SOS1 INHIBITORS
    Publication number: 20250382290
    Abstract: The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: June 23, 2023
    Publication date: December 18, 2025
    Applicant: MIRATI THERAPEUTICS, INC.
    Inventors: MATTHEW ARNOLD MARX, JOHN MICHAEL KETCHAM, CHRISTOPHER RONALD SMITH, JOHN DAVID LAWSON, AARON CRAIG BURNS, XIAOLUN WANG, SVITLANA KULYK, ANTHONY IVETAC
  • TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS
    Publication number: 20250368649
    Abstract: The present invention relates to compounds that inhibit at least one of KRas wild type, KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: June 13, 2023
    Publication date: December 4, 2025
    Inventors: Xiaolun WANG, Anthony IVETAC, Svitlana KULYK, John David LAWSON, Matthew Arnold MARX, Christopher Ronald SMITH
  • Tetrahydropyridopyrimidine pan-KRas inhibitors
    Patent number: 12421253
    Abstract: The present invention relates to compounds that inhibit at least one of KRas wild type, KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Grant
    Filed: April 24, 2024
    Date of Patent: September 23, 2025
    Assignee: Mirati Therapeutics, Inc.
    Inventors: Xiaolun Wang, Anthony Ivetac, Svitlana Kulyk, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith
  • SOS1 INHIBITORS
    Publication number: 20250270220
    Abstract: The present invention relates to methods of treating cancer using compounds that inhibit Son of sevenless homolog 1 (SOS1) activity and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: May 7, 2025
    Publication date: August 28, 2025
    Applicant: MIRATI THERAPEUTICS, INC.
    Inventors: Matthew Arnold Marx, John Michael Ketcham, Christopher Ronald Smith, John David Lawson, Aaron Craig Burns, Xiaolun Wang, Svitlana Kulyk, Anthony Ivetac
  • SOS1 INHIBITORS
    Publication number: 20250059182
    Abstract: The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: June 21, 2022
    Publication date: February 20, 2025
    Inventors: John Michael Ketcham, Christopher Ronald Smith, Matthew Arnold Marx, Xiaolun Wang, Aaron Craig Burns, Svitlana Kulyk, Anthony Ivetac, John David Lawson
  • TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS
    Publication number: 20240376127
    Abstract: The present invention relates to compounds that inhibit at least one of KRas wild type, KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: April 24, 2024
    Publication date: November 14, 2024
    Inventors: Xiaolun Wang, Anthony Ivetac, Svitlana Kulyk, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith
  • Aminopyridine-based MTA-Cooperative PRMT5 Inhibitors
    Publication number: 20240368153
    Abstract: The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: June 29, 2022
    Publication date: November 7, 2024
    Inventors: Christopher Ronald Smith, Svitlana Kulyk, Matthew Arnold Marx, John David Lawson, Anthony Ivetac, Xiaolun Wang, Aaron Craig Burns
  • MTA-Cooperative PRMT5 Inhibitors
    Publication number: 20240208912
    Abstract: Disclosed are compounds of Formula IIA, IA-1, IIB, IIB-1, IIC and IIC-1: and pharmaceutical compositions and methods of use thereof These compounds inhibit Protein Arginine M-Methyl Transferase 5 (PRMT5) activity and are useful in methods and pharmaceutical compositions for treating cancer.
    Type: Application
    Filed: March 11, 2022
    Publication date: June 27, 2024
    Inventors: Thomas P. Bobinski, Christopher Ronald Smith, Matthew Arnold Marx, John Michael Ketcham, Aaron Craig Burns, John David Lawson, Svitlana Kulyk, Jon Kuehler, Anthony Ivetac
  • Tetrahydropyridopyrimidine pan-KRas inhibitors
    Patent number: 11999753
    Abstract: The present invention relates to compounds that inhibit at least one of KRas wild type, KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: June 4, 2024
    Assignee: MIRATI THERAPEUTICS, INC.
    Inventors: Xiaolun Wang, Anthony Ivetac, Svitlana Kulyk, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith
  • QUINAZOLINE PAN-KRas INHIBITORS
    Publication number: 20240025907
    Abstract: The present invention relates to compounds that inhibit at least one of KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: August 2, 2023
    Publication date: January 25, 2024
    Inventors: Xiaolun Wang, Anthony Ivetac, Svitlana Kulyk, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith
  • SOS1 INHIBITORS
    Publication number: 20230312482
    Abstract: The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: July 27, 2021
    Publication date: October 5, 2023
    Inventors: Matthew Arnold Marx, John Michael Ketcham, Christopher Ronald Smith, John David Lawson, Anthony Ivetac
  • SOS1 inhibitors
    Patent number: 11702418
    Abstract: The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: July 18, 2023
    Assignee: MIRATI THERAPEUTICS, INC.
    Inventors: Matthew Arnold Marx, John Michael Ketcham, Christopher Ronald Smith, John David Lawson, Aaron Craig Burns, Xiaolun Wang, Svitlana Kulyk, Anthony Ivetac
  • SOS1 INHIBITORS
    Publication number: 20230137886
    Abstract: The present invention relates to methods of treating cancer using compounds that inhibit Son of sevenless homolog 1 (SOS1) activity and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: November 29, 2022
    Publication date: May 4, 2023
    Inventors: Matthew Arnold Marx, John Michael Ketcham, Christopher Ronald Smith, John David Lawson, Aaron Craig Burns, Xiaolun Wang, Svitlana Kulyk, Anthony Ivetac
  • MTA-Cooperative PRMT5 Inhibitors
    Publication number: 20230054883
    Abstract: The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: September 12, 2022
    Publication date: February 23, 2023
    Inventors: Thomas P. Bobinski, Christopher Ronald Smith, Matthew Arnold Marx, John Michael Ketcham, Aaron Craig Burns, John David Lawson, Svitlana Kulyk, Jon Kuehler, Anthony Ivetac
  • MTA-cooperative PRMT5 inhibitors
    Patent number: 11492351
    Abstract: The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds of Formula (I) to pharmaceutical compositions comprising compounds of Formula (I) and to methods of use thereof, such as methods of treating cancer using the compounds of Formula (I) and pharmaceutical compositions comprising those compounds.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: November 8, 2022
    Assignee: Mirati Therapeutics, Inc.
    Inventors: Thomas P. Bobinski, Christopher Ronald Smith, Matthew Arnold Marx, John Michael Ketcham, Aaron Craig Burns, John David Lawson, Svitlana Kulyk, Jon Kuehler, Anthony Ivetac
  • MTA-cooperative PRMT5 inhibitors
    Patent number: 11479551
    Abstract: The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds of Formula (I) to pharmaceutical compositions comprising compounds of Formula (I) and to methods of use thereof, such as methods of treating cancer using the compounds of Formula (I) and pharmaceutical compositions comprising those compounds.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: October 25, 2022
    Assignee: Mirati Therapeutics, Inc.
    Inventors: Thomas P. Bobinski, Christopher Ronald Smith, Matthew Arnold Marx, John Michael Ketcham, Aaron Craig Burns, John David Lawson, Svitlana Kulyk, Jon Kuehler, Anthony Ivetac
  • TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS
    Publication number: 20220194961
    Abstract: The present invention relates to compounds that inhibit at least one of KRas wild type, KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: December 16, 2021
    Publication date: June 23, 2022
    Inventors: Xiaolun Wang, Anthony Ivetac, Svitlana Kulyk, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith
  • SOS1 INHIBITORS
    Publication number: 20210188857
    Abstract: The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: December 18, 2020
    Publication date: June 24, 2021
    Inventors: Matthew Arnold Marx, John Michael Ketcham, Christopher Ronald Smith, John David Lawson, Aaron Craig Burns, Xiaolun Wang, Svitlana Kulyk, Anthony Ivetac